Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C14H14N8O4S3 |
Molecular Weight | 454.507 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN4C=NN=N4)C(O)=O
InChI
InChIKey=MLYYVTUWGNIJIB-BXKDBHETSA-N
InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
Molecular Formula | C14H14N8O4S3 |
Molecular Weight | 454.507 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Cefazolin is a semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, cefazolin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins. Cefazolin is used to treat bacterial infections of the skin, moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. This drug also can be used for perioperative prophylaxis.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/3266730 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
|||
Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
|||
Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
|||
Curative | ANCEF Approved UseCefazolin for Injection, USP is indicated in the treatment of the following infections due to susceptible organisms: Respiratory Tract Infections: due to S. penumoniae, S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of cefazolin in the subsequent prevention of rheumatic fever are not available. Urinary Tract Infections: due to E. coli, P. mirabilis. Skin and Skin Structure Infections: due to S. aureus (including beta-lactamase-producing strains), S. pyogenes, and other strains of streptococci. Biliary Tract Infections: due to E. coli, various strains of streptococci, P. mirabilis and S. aureus. Bone and Joint Infections: due to S. aureus. Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis. Septicemia: due to S. pneumoniae, S. aureus (including beta-lactamase-producing strains), P. mirabilis, E. coli. Endocarditis: due to S. aureus (including beta-lactamase-producing strains) and S. pyogenes. Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefazolin. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of cefazolin should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date1.18540796E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
280.9 μg/mL |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFAZOLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
509.9 μg × h/mL |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFAZOLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.01 h |
2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered: |
CEFAZOLIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
4 g 2 times / day multiple, intravenous Studied dose Dose: 4 g, 2 times / day Route: intravenous Route: multiple Dose: 4 g, 2 times / day Sources: |
healthy, 21 to 35 years n = 7 Health Status: healthy Age Group: 21 to 35 years Sex: M Population Size: 7 Sources: |
Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (14.3%) Sources: |
1.5 g 8 times / day multiple, intravenous Highest studied dose Dose: 1.5 g, 8 times / day Route: intravenous Route: multiple Dose: 1.5 g, 8 times / day Sources: |
unhealthy, 21-34 years n = 4 Health Status: unhealthy Condition: endocarditis Age Group: 21-34 years Sex: M+F Population Size: 4 Sources: |
|
1 g 4 times / day multiple, intravenous Recommended Dose: 1 g, 4 times / day Route: intravenous Route: multiple Dose: 1 g, 4 times / day Sources: |
healthy, 75 years n = 1 Health Status: healthy Age Group: 75 years Sex: F Population Size: 1 Sources: |
Other AEs: Pseudomembranous colitis... |
1 g 3 times / day multiple, intravenous Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy n = 75 Health Status: unhealthy Condition: closed fractures Population Size: 75 Sources: |
Other AEs: Infection... |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Rash | 14.3% Disc. AE |
4 g 2 times / day multiple, intravenous Studied dose Dose: 4 g, 2 times / day Route: intravenous Route: multiple Dose: 4 g, 2 times / day Sources: |
healthy, 21 to 35 years n = 7 Health Status: healthy Age Group: 21 to 35 years Sex: M Population Size: 7 Sources: |
Pseudomembranous colitis | 1 g 4 times / day multiple, intravenous Recommended Dose: 1 g, 4 times / day Route: intravenous Route: multiple Dose: 1 g, 4 times / day Sources: |
healthy, 75 years n = 1 Health Status: healthy Age Group: 75 years Sex: F Population Size: 1 Sources: |
|
Infection | serious, 15 patients | 1 g 3 times / day multiple, intravenous Dose: 1 g, 3 times / day Route: intravenous Route: multiple Dose: 1 g, 3 times / day Sources: |
unhealthy n = 75 Health Status: unhealthy Condition: closed fractures Population Size: 75 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Relationship between the transport and toxicity of cephalosporins in the kidney. | 1975 Aug |
|
Hemolysis induced by cefazolin and cephalothin in a patient with penicillin sensitivity. | 1978 May-Jun |
|
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera. | 1981 Jan |
|
Cephalosporin-induced cholestatic jaundice. | 1982 Aug 7 |
|
Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. The International Antimicrobial Therapy Project Group of the European Organization for Research and Treatment of Cancer. | 1983 Oct |
|
[Nephrotoxicity of cefodizime sodium in rats--single and 14-day repeated intravenous administration]. | 1988 Jun |
|
Drugs as allergens: an immunoassay for detecting IgE antibodies to cephalosporins. | 1990 |
|
Comparison of in vitro antimicrobial susceptibilities of Mycobacterium avium-M. intracellulare strains from patients with acquired immunodeficiency syndrome (AIDS), patients without AIDS, and animal sources. | 1990 Jul |
|
Use of charge-transfer complexation in the spectrophotometric analysis of certain cephalosporins. | 2001 Jul 6 |
|
Fine structural recognition specificities of IgE antibodies distinguishing amoxicilloyl and amoxicillanyl determinants in allergic subjects. | 2001 Sep-Oct |
|
Effect of water content on the solid-state stability in two isomorphic clathrates of cephalosporin: cefazolin sodium pentahydrate (alpha form) and FK041 hydrate. | 2002 Jun |
|
Fluorimetric determination of some antibiotics in raw material and dosage forms through ternary complex formation with terbium (Tb(3+)). | 2003 Aug 21 |
|
The release of cefazolin and gentamicin from biodegradable PLA/PGA beads. | 2004 Apr 1 |
|
Antibiotic activity and synergistic effect of antimicrobial peptide against pathogens from a patient with gallstones. | 2004 Aug 27 |
|
Antitumor activity of common antibiotics against superficial bladder cancer. | 2004 Mar |
|
In situ investigation of drug diffusion in hydrogels by the refractive index method. | 2004 May 15 |
|
Potassium permanganate-glyoxal chemiluminescence system for flow injection analysis of cephalosporin antibiotics: cefalexin, cefadroxil, and cefazolin sodium in pharmaceutical preparations. | 2004 Sep 8 |
|
Graft infectivity of rifampin and silver-bonded polyester grafts to MRSA contamination. | 2005 Sep-Oct |
|
Hypotonia during amikacin administration in a patient treated with continuous ambulatory peritoneal dialysis. | 2006 |
|
Attenuation of ischemia-reperfusion injury by ascorbic acid in the canine renal transplantation. | 2006 Dec |
|
Chemiluminescence flow-injection analysis of beta-lactam antibiotics using the luminol-permanganate reaction. | 2006 Jul-Aug |
|
Infective endocarditis with an aortic periannular abscess extending along the right coronary artery. | 2006 Jun |
|
Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. | 2006 May |
|
Epileptogenic activity of methicillin-resistant Staphylococcus aureus (MRSA) antibiotics in rats. | 2006 Oct |
|
Stability of cefazolin sodium in four heparinized and non-heparinized dialysate solutions at 38 degrees C. | 2006 Sep-Oct |
|
[Physical and chemical characteristics of a new cefazolin sodium hydrate crystal]. | 2008 Aug |
|
Treatment of sinusitis with corticosteroids in combination with antibiotics in experimentally induced rhinosinusitis. | 2008 May |
|
Trends in antibacterial use in US academic health centers: 2002 to 2006. | 2008 Nov 10 |
|
Kinetic spectrophotometric determination of certain cephalosporins in pharmaceutical formulations. | 2009 |
|
[Antibiotic susceptibility of pathogenic bacteria isolated from 893 children with lower respiratory infection in Guiyang]. | 2009 Dec |
|
Reactive astrocytes in glial scar attract olfactory ensheathing cells migration by secreted TNF-alpha in spinal cord lesion of rat. | 2009 Dec 3 |
|
The effects of methylprednisolone and cefazolin sodium on antioxidant status in experimentally induced maxillary sinusitis. | 2009 Oct |
|
Laser-induced silver nanoparticles on titanium oxide for photocatalytic degradation of methylene blue. | 2009 Oct 29 |
|
Evaluating intra- and inter-examiner reproducibility in histometric measurement: one-wall intrabony periodontal defects in beagle dogs. | 2010 Aug |
|
Histological characteristics of newly formed cementum in surgically created one-wall intrabony defects in a canine model. | 2010 Feb |
|
Osteoid osteoma of the femur in a 7-month-old infant treated with radiofrequency ablation. | 2010 Nov |
|
Stability of fortified cefazolin ophthalmic solutions prepared in artificial tears containing surfactant-based versus oxidant-based preservatives. | 2010 Oct |
|
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. | 2015 May 18 |
Sample Use Guides
Moderate to severe infections: 500 mg to 1 gram, every 6 to 8 hours; mild infections caused by susceptible
gram-positive cocci: 250 mg to 500 mg, every 8 hours; acute, uncomplicated urinary tract infections: 1 gram, every 12 hours; Pneumococcal pneumonia: 500 mg, every 12 hours; Severe, life threatening infections (e.g., endocarditis, septicemia): 1 gram to 1.5 grams, every 6 hours
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4451358
Susceptibilities of 259 isolates of pathogenic bacteria to cefazolin were measured by broth and agar dilution procedures. Beta-hemolytic streptococci were inhibited by 0.25 mug/ml, whereas Staphylococcus aureus and alphahemolytic streptococci were inhibited by 2.0 mug/ml. Enterococci were resistant to less than 32 mug/ml. Wide variation was seen with gram-negative species. Most isolates of Klebsiella species and Proteus mirabilis were inhibited by 4.0 or 8.0 mug/ml. Escherichia coli were less susceptible, and most isolates of Pseudomonas aeruginosa, Serratia species, and Enterobacter species were resistant to 128 mug/ml.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:20:19 UTC 2023
by
admin
on
Fri Dec 15 15:20:19 UTC 2023
|
Record UNII |
IHS69L0Y4T
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
LIVERTOX |
NBK548358
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
LIVERTOX |
NBK547862
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.1
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
WHO-ATC |
J01DB04
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000175488
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
LIVERTOX |
NBK548666
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
WHO-VATC |
QJ51DB04
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
NDF-RT |
N0000011161
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
||
|
WHO-VATC |
QJ01DB04
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1097603
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
474053
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
530
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
CHEMBL1435
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
C28913
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
CEFAZOLIN
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
33255
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
Cefazolin
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
2180
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | RxNorm | ||
|
D002437
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
247-362-8
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
DTXSID2022753
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
25953-19-9
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
SUB07379MIG
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
DB01327
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
IHS69L0Y4T
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
2991
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
100000081793
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
m3188
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | Merck Index | ||
|
3213
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY | |||
|
IHS69L0Y4T
Created by
admin on Fri Dec 15 15:20:19 UTC 2023 , Edited by admin on Fri Dec 15 15:20:19 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR | |||
|
EXCRETED UNCHANGED |
Cefazolin is excreted unchanged in the urine. In the first 6 hours approximately 60% of the drug is excreted in the urine and this increases to 70% to 80% within 24 hours.
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
|
|||